JNJ-54175446

DRUG3 trials

Sponsors

Janssen-Cilag International NV, Janssen Research & Development, LLC

Conditions

Healthy

Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants

CompletedNCT02515955

Janssen-Cilag International NVHealthy

Start: 2015-08-31End: 2016-03-31Updated: 2025-02-03

A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma

CompletedNCT02933762

Janssen Research & Development, LLCHealthy

Start: 2016-09-30End: 2016-11-30Updated: 2025-02-03

A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739

CompletedNCT03088644

Janssen-Cilag International NVHealthy

Start: 2017-03-24End: 2017-11-14Updated: 2025-04-27

Related Papers

Profiling classical neuropsychiatric biomarkers across biological fluids and following continuous lumbar puncture: A guide to sample type and time.

2022-01-154 citations